News | Breast Imaging | January 26, 2017

Major Health Partners Purchases Its First Molecular Breast Imaging Technology

MBI to provide early detection and increased breast cancer diagnosis for women with dense breast tissue and whose cancers weren’t detected by a routine mammogram

Gamma Medica, LumaGEM molecular breast imaging system, MBI technology, Major Health Partners Indiana

January 26, 2017 — Gamma Medica recently announced that through its collaboration with Ohio-based Alpha Imaging, Indiana-based Major Health Partners (MHP) has purchased and installed Gamma Medica’s LumaGEM molecular breast imaging (MBI) system. It is the state’s first LumaGEM and the hospital’s first MBI.

The MBI technology will be offered as a secondary screening and diagnostic tool following mammography, particularly for women with dense breast tissue. The system will enhance early breast cancer detection for women who face a greater risk of breast cancer.

Breast cancer is one of the leading causes of death in women, causing approximately 40,000 annual deaths in the United States alone. More than 40 percent of U.S. women have dense breast tissue, which both increases the risk of developing breast cancer and decreases the visibility of a cancer on conventional mammograms. Until undergoing their first mammogram, most women are unaware of the condition and may not fully understand its potential significance. 

Designed for dense breast tissue, MBI technology significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective, or more, as a secondary screening method compared to full-field ultrasound or magnetic resonance imaging (MRI) with far fewer false positives. Clinical research shows use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities. MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI.

“Alpha Imaging is pleased to have the LumaGEM MBI system in our portfolio,” said Mike Colaiacovo, VP of sales at Alpha Imaging. “Coupled with breast tomosynthesis, MBI allows us to provide a more comprehensive solution to our clients. It’s one more advancement in early detection of breast cancer.”

“The Mayo Clinic and others have shown the utility of MBI for both supplemental screening for breast cancer with underlying dense breast tissue and diagnostic problem-solving in breast healthcare,” said Scott Miller, M.D., radiologist at MHP. “We consider MBI to be an integral component of breast cancer diagnosis, and we were impressed by the data documenting a significant increase in cancer detection rates through use of the LumaGEM MBI system.”

A retrospective study that was published in the American Journal of Roentgenology’s August 2016 issue monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per thousand, an increase from 3 cancers per thousand with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent of these cancers were node negative, indicating they were detected at an early stage and therefore presented a better prognosis.

To educate women about the importance of MBI and breast density, Gamma Medica launched the Be Certain campaign, which aims to give physicians and women access to the most accurate clinical information on breast density and breast cancer detection. In addition to education, Gamma Medica is committed to increasing the number of accurate early breast cancer screenings through installations at major facilities.

For more information: www.gammamedica.com

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...